SUMMARY OF PERFORMANCE

KEY NATIONAL INDICATORS

A&E INDICATORS

Monitor Indicator and threshold:

	Threshold	Monitoring Period
Maximum of four hours from arrival to admission/ transfer/ discharge	95%	Quarterly

EKHUFT Performance:

Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mch
94.7	94.5	93.8%	92.4%	95%	92.9%						

REFERRAL TO TREATMENT WAITING TIME PERFORMANCE

Monitor Indicator and threshold:

	Threshold	Monitoring Period
Maximum time of 18 weeks from point of referral to treatment in aggregate – admitted.	90%	Quarterly
Maximum time of 18 weeks from point of referral to treatment in aggregate – non-admitted.	95%	Quarterly
Maximum time of 18 weeks from point of referral to treatment in aggregate – patients on an incomplete pathway	92%	Quarterly

EKHUFT Performance:

Pathway	< 18 Weeks	>18 Weeks	Total	% Compliance	52 Week waiters	Backlog Position
Non-Admitted Pathway	8,445	204	8,649	97.6%		
Admitted Pathway	3,084	460	3,544	87.0%		1,366
Incomplete Pathways	30,652	2,216	32,868	93.3%	5	

Table 3.1 – RTT Position Compliance by Pathway (September 2014)

CANCER TARGETS

Monitor Indicator and threshold:

	Threshold	Monitoring Period
All cancers: 62 day wait for first treatment from: • Urgent GP referral for suspected cancer	85%	Quarterly
NHS cancer screening service referral All cancers: 31 day wait for second or subsequent	90%	
treatment comprising:	94% 98% 94%	Quarterly
All cancers: 31 day wait from diagnostics to first treatment	96%	Quarterly
Cancer: two week wait from referral to date first seen comprising: • All urgent referrals (cancer suspected) • For symptomatic breast patients (cancer not initially suspected)	93% 93%	Quarterly

EKHUFT Performance:

AS AT	2 Wee	k Wait		31 Day	62 Day		
19-Oct-14	All Cancers	Symptomatic Breast	Diag to First Treat Surgery		Drug	Urgent GP Referral	Screening Referral
Target 2014/15	93%	93%	96%	94%	98%	85%	90%
Q1 14/15	93.50%	92.37%	99.07%	95.74%	99.14%	85.65%	95.60%
July	93.70%	88.89%	99.00%	95.65%	100.00%	82.03%	87.72%
August	93.15%	81.82%	99.28%	90.32%	100.00%	83.80%	91.49%
September*	93.04%	74.83%	97.72%	88.24%	100.00%	81.65%	75.00%

^{*}unvalidated position

Table 6.1 – Cancer Performance